Introduction {#sec1-1744806919848929}
============

Catechol-O-methyltransferase (COMT) is a metabolizing enzyme that regulates the reuptake and degradation of extracellular catecholamines via transfer of a methyl group.^[@bibr1-1744806919848929],[@bibr2-1744806919848929]^ A widely investigated single-nucleotide polymorphism (SNP) in the COMT coding region yields a G to A substitution in codon 158 (rs4680).^[@bibr3-1744806919848929],[@bibr4-1744806919848929]^ The rs4680 SNP is often referred to as the COMT Val158Vet polymorphism. The G to A substitution alters the translated amino acid from valine (Val) to methionine (Met) which reduces the activity of the COMT enzyme to 25% of the wild type due to diminished thermostability of the enzyme.^[@bibr3-1744806919848929],[@bibr5-1744806919848929]^

The COMT Val158Met polymorphism has been associated with alterations in pain perception and opioid responsiveness in experimental pain studies^[@bibr6-1744806919848929][@bibr7-1744806919848929]--[@bibr8-1744806919848929]^ and perioperative cohorts of adults with postoperative pain.^[@bibr9-1744806919848929][@bibr10-1744806919848929]--[@bibr11-1744806919848929]^ However, the influence of the COMT Val158Met polymorphism on pain perception in chronic pain patients receiving daily opioid therapy has not been previously reported. This is important because preclinical studies suggest that opioid-induced hyperalgesia (OIH) is mediated, in part, by ß~2/3~ adrenergic mechanisms that are responsive to varying levels of COMT enzymatic activity.^[@bibr12-1744806919848929][@bibr13-1744806919848929][@bibr14-1744806919848929]--[@bibr15-1744806919848929]^ Therefore, the primary aim of this study was to investigate the influence of the COMT Val158Met polymorphism on heat pain (HP) perception in a cohort of adults receiving daily opioid therapy for chronic pain. This study utilized a parameter of HP perception that has been reported to be an indicator of OIH in adults with chronic pain.^[@bibr16-1744806919848929],[@bibr17-1744806919848929]^ Portions of this data set have been previously published.^[@bibr18-1744806919848929][@bibr19-1744806919848929]--[@bibr20-1744806919848929]^

Methods {#sec2-1744806919848929}
=======

Participants {#sec3-1744806919848929}
------------

The study protocol was approved by the Mayo Foundation Institutional Review Board, and written informed consent was provided by all patients prior to study participation. As previously reported,^[@bibr18-1744806919848929][@bibr19-1744806919848929]--[@bibr20-1744806919848929]^ all adults consecutively admitted to the Mayo Comprehensive Pain Rehabilitation Center from March 2009 to March 2010 were eligible for study recruitment. During this time period, 524 patients were admitted. Inclusion criteria were met by 300 patients, and these individuals were successfully recruited for study participation. Inclusion criteria comprised (1) admission to the pain treatment program, (2) chronic noncancer pain for more than three-month duration, and (3) age ≥18 years. Exclusion criteria included a major medical (e.g., severe cardiac or pulmonary disease), surgical (e.g., spine or intraabdominal surgery within six months of admission), or psychiatric disorder (e.g., schizophrenia, dementia) that precluded full participation in the three-week outpatient treatment program.

Upon admission to the outpatient pain treatment program, 153 of the 300 patients were using daily opioids. Quantitative sensory testing (QST) was not performed on 11 patients due to lack of available study personnel. Thus, the study cohort was comprised of 142 patients.

Study setting {#sec4-1744806919848929}
-------------

The clinical setting has been previously described.^[@bibr21-1744806919848929]^ In brief, the outpatient pain rehabilitation program was three-week duration, and patients attended 8 h daily. A cognitive behavioral model was the basis of treatment. The primary goal of treatment was restoration of physical and emotional functioning. Patients were involved in daily educational group sessions about management of pain-related anxiety and depressive symptoms, relaxation training, and stress management. Other group sessions included daily physical and occupational therapy, identification and elimination of pain behaviors, and activity moderation.

Demographic and clinical characteristics {#sec5-1744806919848929}
----------------------------------------

Upon admission, baseline demographic and clinical characteristics were collected including age, sex, race and ethnicity, pain diagnosis, and pain duration.

Determination of morphine equivalent dose {#sec6-1744806919848929}
-----------------------------------------

The daily opioid dose of each patient was determined by self-report and review of pharmacy records on admission to the pain treatment program, as previously described.^[@bibr22-1744806919848929]^ Using a software program available at our pain treatment program,^[@bibr23-1744806919848929]^ the daily opioid dose was converted to a morphine equivalent dose (MED) expressed in milligrams (mg) per day.^[@bibr17-1744806919848929]^

Genotyping {#sec7-1744806919848929}
----------

As previously described,^[@bibr18-1744806919848929]^ genotyping was performed using ABI TaqMan reagents (Applied Biosystems, Foster City, CA, now ThermoFisher Scientific, Waltham, MA), according to manufacturer's instructions (10 ng DNA). Primers and probes were specific for COMT rs4680 (C_25746809-50). End reactions were read on an ABI Prism 7900 ht using ABI Sequence Detection Software; allelic discrimination and genotype data were generated in an electronic data set.

Measures {#sec8-1744806919848929}
--------

All self-report measures (Pain Catastrophizing Scale (PCS), verbal pain rating scale) were completed on the day of admission, and QST was performed one day following admission to the pain treatment program.

### HP perception {#sec9-1744806919848929}

QST was performed using the Computer Aided Sensory Evaluator IV (CASE IV; WR Medical Electronics, Stillwater, MN) system based on the method of levels.^[@bibr24-1744806919848929][@bibr25-1744806919848929]--[@bibr26-1744806919848929]^ This QST devise has been previously used to assess HP perception at our pain treatment program.^[@bibr16-1744806919848929],[@bibr17-1744806919848929],[@bibr19-1744806919848929],[@bibr27-1744806919848929],[@bibr28-1744806919848929]^ A series of heat stimuli of variable magnitude interspersed with null stimuli are delivered by the CASE IV system in random order through a thermode with a surface area of 10 cm^2^. The protocol includes standardized test instructions and procedures, stimulus wave form, null stimulus, and nonrepeating stepping algorithm between the different levels of heat stimuli.^[@bibr24-1744806919848929][@bibr25-1744806919848929]--[@bibr26-1744806919848929],[@bibr29-1744806919848929]^ During testing, the subject is masked to the stimulus magnitude including all null stimuli. Following each stimulus, the intensity is rated by the subject on an 11-point scale (0 denotes no pain and 10 denotes the most intense possible pain). The test is completed either when the maximum stimulus has been delivered or when the stimulus intensity has been rated as ≥5.

The CASE IV system delivers 25 different magnitudes of heat stimuli expressed in units of just noticeable difference (JND).^[@bibr24-1744806919848929],[@bibr25-1744806919848929],[@bibr30-1744806919848929]^ Two elements comprise the magnitude of each level of HP stimuli: (1) temperature and (2) duration of exposure. The baseline temperature is 34°C, and the thermal rate of rise is 4°C/s. The temperature increases exponentially, and the thermode reaches 48°C for 1 s at level 21. For levels 22, 23, and 24, the temperature remains at 48°C for 1.5, 5, and 10 s, respectively. Level 25 is the maximum heat stimulus where the temperature reaches 49°C for a duration of 10 s. Higher temperatures are not used in order to avoid thermal tissue injury.

A quadratic regression equation is then fitted to the pain ratings, and the CASE IV software (WR TestWorks, version 2.0, WR Electronics) calculates HP 0.5, HP 5, and HP 5--0.5. HP 0.5 is defined as the midpoint between a nonpainful stimulus and the least stimulus magnitude needed to elicit a threshold pain sensation. The stimulus magnitude necessary to elicit a pain rating of 5, indicating intermediately intense pain, is defined as HP 5. HP 5--0.5 is a measure of the slope of the line connecting HP 0.5 and HP 5, otherwise referred to as the stimulus response slope. The raw sensory data, recorded in units of JND, are adjusted by the CASE IV software program for anthropometric characteristics known to influence the pain perception including age, sex, height, weight, body surface area, body mass index, and body region of testing.^[@bibr31-1744806919848929][@bibr32-1744806919848929]--[@bibr33-1744806919848929]^ The raw sensory data are then converted to a standardized unit, termed normal deviate (ND), by the CASE IV software program using the means and standard deviations (SDs) from a population of normal individuals (N = 330) without neurological disease.^[@bibr31-1744806919848929]^ Subjects who comprised the randomly selected normative population were stratified by hemidecade and sex where every five-year span in age, starting at age 18 and extending through age 74, contained 15 men and 15 women.^[@bibr31-1744806919848929]^ In the normal distribution of ND values from this population, an ND value of 0 corresponds to the 50th percentile and has an SD of 1. An ND \< 0 indicates a progressive trend toward increased pain sensitivity or hyperalgesia (ND = −2.33 corresponds to the 1st percentile) ([Figure 1](#fig1-1744806919848929){ref-type="fig"}). Conversely, an ND \> 0 indicates a progressive trend toward reduced pain sensitivity or hypoalgesia (ND = 2.33 corresponds to the 99th percentile). Normative values of HP perception are available for the right and left foot, lower legs, thighs, dorsum of the hands, arms, and shoulders.^[@bibr25-1744806919848929],[@bibr31-1744806919848929]^

![Plotted values depicting a hyperalgesic, normal, and hypoalgesic HP response using the CASE IV system. The test algorithm starts at a stimulus magnitude of 13 JND. The shapes indicate the patient's pain rating at the respective stimulus magnitudes. Hyperalgesia is characterized by a leftward shift in HP 0.5 and HP 5 and an increase in the stimulus response slope which yields progressively negative (more hyperalgesic) values of HP 5--0.5. JND: just noticeable difference; HP: heat pain.](10.1177_1744806919848929-fig1){#fig1-1744806919848929}

The testing conditions were consistent between subjects, and all QST procedures were conducted in a specifically designed room. The entire testing procedure takes approximately 5 min to complete.^[@bibr29-1744806919848929]^ To ensure consistent assessability between subjects, the dorsal surface of the nondominant hand was used as the anatomic site for all tests. At the time of testing, all patients were receiving their admission opioid dose.

### Pain catastrophizing {#sec10-1744806919848929}

The PCS is a 13-item self-report questionnaire that assesses negative cognitions and emotions associated with actual or anticipated pain experiences.^[@bibr34-1744806919848929]^ Scores of the PCS range from 0 to 52 with higher scores indicating levels of negative cognitions and emotions associated with pain experiences.

### Pain intensity {#sec11-1744806919848929}

Pain intensity was assessed using the 11-point verbal rating scale (VRS) where 0 indicated no pain and 10 indicated the most intense possible pain. The validity of the VRS has been well established.^[@bibr35-1744806919848929][@bibr36-1744806919848929]--[@bibr37-1744806919848929]^

Statistical analyses {#sec12-1744806919848929}
--------------------

Demographic and clinical characteristics were summarized for each genotype group. Mean and SD were reported for continuous variables, and count and proportion were reported for categorical variables. For MED, the median and 25th to 75th interquartile range were reported. For all measures of HP, one-sample Kolmogorov--Smirnov tests were performed to determine the normal distribution of the data. Group differences in demographic and clinical characteristics based on genotype were assessed using nonparametric tests (Kruskal--Wallis Test) for continuous variables, and χ^2^ test was used for categorical variables. The genotype distribution at the COMT Val158Met polymorphism was tested for departure from Hardy--Weinberg equilibrium using a χ^2^ test.^[@bibr38-1744806919848929]^

Two genotype models were used to evaluate the association of the COMT polymorphism with standardized measures of HP. First, an additive model was used where the three genotypes were coded as a quantitative variable indicating the number of Met alleles (Val/Val = 0, Val/Met = 1, Met/Met = 2). Second, a codominant model was used where genotype was used as a categorical variable (Val/Val vs. Val/Met vs. Met/Met). Both additive and codominant genotype models have been used extensively to study the influence of the COMT Val158Met polymorphism on a range of pain-related outcomes.^[@bibr11-1744806919848929],[@bibr18-1744806919848929],[@bibr39-1744806919848929][@bibr40-1744806919848929][@bibr41-1744806919848929][@bibr42-1744806919848929]--[@bibr43-1744806919848929]^ Multivariate linear regression analyses were used to evaluate the associations between measures of HP (dependent variable) and genotype for both genotype models. For the codominant model, exploratory post hoc pairwise comparisons were performed to investigate the differences between specific genotype groups (Val/Val vs. Val/Met; Val/Val vs. Met/Met; Val/Met vs. Met/Met). Covariates in the regression models included pain catastrophizing and MED because these variables have been previously reported to influence the HP.^[@bibr16-1744806919848929],[@bibr17-1744806919848929],[@bibr28-1744806919848929]^

The level of significance for all tests was set at *P* ≤ .05, and all analyses were completed using SPSS (IBM, Inc.; Version 21.0, Chicago, IL).

Results {#sec13-1744806919848929}
=======

Demographic and clinical characteristics {#sec14-1744806919848929}
----------------------------------------

[Table 1](#table1-1744806919848929){ref-type="table"} contains the demographic and clinical characteristics for the study cohort. The distribution of the COMT Val158Met genotype was 25% (N = 35) for Val/Val, 41% for Val/Met (N = 59), and 34% for Met/Met (N = 48). There was no departure from Hardy--Weinberg equilibrium (χ^2^ = 3.73, *P* \> 0.05). The majority of patients were white females with a mean age of 47.4 years and mean pain duration of 9.8 years. The median MED was 60.0 mg/day, and no significant group differences based on genotype were observed for pain catastrophizing or pain intensity.

###### 

Demographic and clinical characteristics.

![](10.1177_1744806919848929-table1)

  Characteristic                                      Total (N = 142)        COMT Val158Met genotype   *P* ^[a](#table-fn2-1744806919848929){ref-type="table-fn"}^                          
  --------------------------------------------------- ---------------------- ------------------------- ------------------------------------------------------------- ---------------------- -------
  Age, years (mean ± SD)                              47.4 ± 13.0            48.6 ± 13.4               45.6 ± 13.0                                                   48.9 ± 12.8            0.351
  Sex, no. female (%)                                 87 (61.3)              17 (48.6)                 39 (66.1)                                                     31 (64.6)              0.204
  Race/ethnicity                                                                                                                                                                            0.567
   White                                              137 (96.5)             33 (94.3)                 58 (98.3)                                                     46 (95.8)              
   Other                                              5 (3.5)                2 (6.1)                   1 (1.7)                                                       2 (4.2)                
  Pain duration, years                                9.8 (8.9)              9.6 (8.4)                 11.0 (10.7)                                                   8.6 (6.6)              0.463
  Smoking status                                                                                                                                                                            0.712
   Current smoker                                     27 (19.0)              5 (14.3)                  12 (20.3)                                                     10 (20.8)              
   Nonsmoker                                          115 (81.0)             30 (85.7)                 47 (79.7)                                                     38 (79.2)              
  Primary pain diagnosis                                                                                                                                                                    0.709
   Low back, neck pain                                50 (35.2)              10 (28.6)                 23 (39.0)                                                     17 (35.4)              
   Fibromyalgia, headache, facial, generalized pain   51 (35.9)              11 (31.4)                 22 (37.3)                                                     18 (37.5)              
   Abdominal, pelvic, chest                           23 (16.2)              9 (25.7)                  7 (11.7)                                                      7 (14.6)               
   Upper and lower extremity                          18 (12.7)              5 (14.3)                  7 (11.9)                                                      6 (12.5)               
  Daily MED (mg/day) median (IQR)                     60.0 (30.0 to 135.0)   33.8 (22.5 to 105.0)      67.5 (30.0 to 150.0)                                          60.0 (30.0 to 135.0)   0.125
  Pain catastrophizing                                28.1 (10.2)            28.7 (10.3)               26.1 (10.0)                                                   30.1 (10.2)            0.132
  Pain intensity                                      6.3 (2.0)              6.6 (1.6)                 6.2 (2.1)                                                     6.1 (2.0)              0.472

Note: COMT: catechol-O-methyltransferase; MED: morphine equivalent dose; IQR: interquartile range; pain intensity: verbal pain rating scale; pain catastrophizing: Pain Catatrophizing Scale; SD: standard deviation.

^a^Kruskal--Wallis Test for continuous variables and χ^2^ test for categorical variables.

Association of HP perception and COMT Val158Met genotype effect model {#sec15-1744806919848929}
---------------------------------------------------------------------

[Figure 2](#fig2-1744806919848929){ref-type="fig"} depicts the distribution of ND values for HP 0.5, HP 5, and HP 5--0.5. The values of HP 0.5 and HP 5--0.5 were normally distributed (Kolmogorov--Smirnov Z *P* \> 0.5), but the values of HP 5 were not normally distributed (Kolmogorov--Smirnov test, *P* \< 0.5). [Table 2](#table2-1744806919848929){ref-type="table"} contains the mean values of HP 0.5, HP 5, and HP 5--0.5 for each genotype. A main effect of genotype was observed for HP 5--0.5 (*P* = 0.028). In multivariate linear regression analysis adjusted for MED and PCS scores, no significant association was observed between HP 5--0.5 and genotype under the additive model of allele effects (*P* = 0.836) ([Table 3](#table3-1744806919848929){ref-type="table"}). However, under the codominant model of allele effects, exploratory post hoc pairwise comparison adjusted for MED and PCS scores demonstrated that individuals with the Val/Met genotype had significantly lower values of HP 5--0.5 compared to individuals with the Val/Val (*P* = 0.039) and Met/Met (*P* = 0.023) genotypes. No significant association was observed for HP 5--0.5 and the Val/Val and Met/Met genotypes.

![Distribution of HP 0.5, HP 5, and HP 5--0.5 expressed in units of normal deviates. The values of HP 0.5 and HP 5--0.5 were normally distributed (Kolmogorov--Smirnov Z, *P* \> 0.05), but the values of HP 5 were not normally distributed (Kolmogorov--Smirnov Z, *P* \< 0.05). HP: heat pain.](10.1177_1744806919848929-fig2){#fig2-1744806919848929}

###### 

Mean values (± SD) of HP perception for patients using opioids based on COMT Val158Met genotype.

![](10.1177_1744806919848929-table2)

  HP parameter     COMT Val158Met genotype                                 
  ---------------- ------------------------- -------------- -------------- -------
  HP 0.5                                                                   
   ND, mean ± SD   −0.63 ± 1.41              −0.29 ± 1.26   −0.62 ± 1.12   0.406
  HP 5                                                                     
   ND              −0.49 ± 1.90              −0.67 ± 1.42   −0.45 ± 1.57   0.818
  HP 5 − 0.5                                                               
   ND              0.32 ± 1.46               −0.35 ± 1.30   0.24 ± 1.18    0.028
                                                                           

Note: COMT: catechol-O-methyltransferase; HP: heat pain; SD: standard deviation; ND: normal deviate.

^a^Kruskal--Wallis test.

###### 

Linear regression analysis of the COMT Val158Met genotype effect model and HP 5--0.5 (dependent variable).

![](10.1177_1744806919848929-table3)

  Genotype effect model   HP 5--0.5                     
  ----------------------- ----------- ----------------- -------
  Additive                0.031       −0.263 to 0.325   0.836
  Codominant                                            
   Val/Met vs. Val/Val    −0.621      −1.21 to −0.032   0.039
   Met/Met vs. Val/Val    0.030       −0.56 to 0.621    0.919
   Val/Met vs. Met/Met    −0.571      −1.06 to −0.081   0.023

Note: All analyses adjusted for morphine equivalent dose and Pain Catastrophizing Scale scores. CI: confidence interval; HP: heat pain.

Discussion {#sec16-1744806919848929}
==========

The main finding of this study was that among patients with chronic pain who were receiving daily opioids, the Val/Met genotype was associated with significantly lower values of HP 5--0.5 compared to the Val/Val and Met/Met genotypes in a multivariate regression model that used a standardized measure of HP perception and was adjusted for MED and PCS scores. The more negative values of HP 5--0.5 indicated that individuals with the Val/Met genotype were hyperalgesic compared to individuals with the Val/Val or Met/Met genotypes.

The influence of the COMT Val158Met polymorphism on pain perception in humans has been investigated with mixed results. In healthy subjects, no significant associations were observed between the Val158Met polymorphism and various methods of delivering HP stimuli using a thermode applied to the skin.^[@bibr44-1744806919848929],[@bibr45-1744806919848929]^ Similarly, no significant associations were observed between the Val158Met polymorphism and pressure pain thresholds in cohorts of adults with fibromyalgia and carpal tunnel syndrome.^[@bibr46-1744806919848929],[@bibr47-1744806919848929]^ However, in a cohort of healthy subjects, the Met/Met genotype was associated with increased sensitivity to a "bone pressure" stimuli compared to the Val/Met and Val/Val genotypes.^[@bibr45-1744806919848929]^ In a study cohort comprised predominately of adults with fibromyalgia, the Met allele was associated with increased sensitivity to electric stimuli,^[@bibr48-1744806919848929]^ and the Met allele was observed to influence the rate of temporal summation to HP in a cohort of healthy subjects.^[@bibr6-1744806919848929]^ Based on these disparate findings, a conclusive understanding of the influence of the COMT Val158Met polymorphism on pain perception is limited by two important factors. First, various modalities of nonstandardized pain stimuli were used, which adversely impact the reproducibility of study findings and limit direct comparisons between studies. The use of standardized values of pain perception has been recommended to reduce within- and between-group variations in sensory data.^[@bibr32-1744806919848929],[@bibr49-1744806919848929],[@bibr50-1744806919848929]^ Second, a large proportion of studies were conducted in healthy subjects, and the findings may not be applicable to individuals with chronic pain.

The absence of a widely recognized effect of the COMT Val158Met polymorphism on pain perception limits the interpretation of studies that have investigated the influence of the polymorphism on the analgesic response to opioids. In a cohort of 43 healthy subjects, no significant effect of the Val158Met polymorphism was observed on the analgesic response to a single intravenous bolus of remifentanil (0.08 mcg/kg) administered prior to a tonic heat skin stimulus of 30 s duration.^[@bibr7-1744806919848929]^ Similar findings were observed in a cohort of 117 postoperative cardiac patients where the analgesic response following an intravenous bolus of morphine 2.5 mg or 7.5 mg was similar for all three Val158Met genotype groups.^[@bibr51-1744806919848929]^ However, in a separate study that involved 38 healthy subjects, the Val/Val genotype compared to the Val/Met and Met/Met genotypes was associated with increased analgesia in response to oral morphine 30 mg administered prior to a series of three heat skin stimuli that were delivered using the QST method of limits.^[@bibr8-1744806919848929]^ These inconsistent findings could be related to (1) methodological differences in how the heat stimulus was delivered, (2) differences in the route of opioid administration and dose equivalency, and (3) differences in the potential hyperalgesic effects of the administered opioids.

The potential mechanisms responsible for our study findings warrant further consideration. The major isoform of the *mu*-opioid receptor (MOR) is a seven-transmembrane (7TM) spanning G-protein coupled receptor, but alternative splicing yields an isoform that has a six-transmembrane (6TM) spanning domain.^[@bibr52-1744806919848929]^ Activation of the 7TM-MOR has inhibitory cellular effects that result in analgesia, and activation of the 6TM-MOR has excitatory effects that result in hyperalgesia.^[@bibr14-1744806919848929],[@bibr52-1744806919848929]^ This is relevant to the influence of COMT on pain perception because the 6TM-MOR isoform heterodimerizes with ß~2~-adrenergic receptors (ß~2~-AR).^[@bibr13-1744806919848929]^ This dimerization is responsible for the hyperalgesic effects associated with 6TM-MOR activation, which can be reversed by ß~2~-AR antagonists.^[@bibr13-1744806919848929]^ The association between OIH and adrenergic function is further supported by preclinical studies that (1) identified an association between OIH and a haplotype block containing the ß~2~-AR gene coding region^[@bibr12-1744806919848929]^ and (2) demonstrated that COMT inhibition increases pain sensitivity through activation of ß~2/3~-AR mechanisms.^[@bibr53-1744806919848929]^ The observations from our study extend the findings of these preclinical studies and suggest that in the context of exposure to exogenous opioids the Val/Met genotype potentiates the effects of the 6TM-MOR/ß~2~-AR heterodimer, which, in turn, contributes to OIH. This is consistent, in part, with previous studies where the Val/Met genotype was associated with enhanced pain sensitivity in humans.^[@bibr6-1744806919848929],[@bibr54-1744806919848929]^

The influence of the Val158Met polymorphism on OIH has important clinical and research implications. In a randomized, double-blind, placebo-controlled crossover pilot study, 40 Caucasian women with temporomandibular disorder were genotyped for COMT polymorphisms and allocated to receive propranolol or placebo.^[@bibr55-1744806919848929]^ Propranolol administration was associated with significant reductions in pain among individuals lacking the COMT high activity haplotype.^[@bibr55-1744806919848929]^ However, the potential effects of propranolol on concurrent opioid use were not investigated. The effects of propranolol on remifentanil-induced hyperalgesia were investigated in a double-blinded, randomized, placebo-controlled, crossover trial that involved 10 healthy subjects.^[@bibr56-1744806919848929]^ In this study that used an experimental model of hyperalgesia, the development of mechanical hyperalgesia following administration of remifentanil was attenuated with coadministration of propranolol.^[@bibr56-1744806919848929]^ Building on the findings of these previous trials, the observations from our study could be used to facilitate the development of clinical trials stratified by COMT activity level and designed to investigate the effects of ß~2~-AR antagonism on clinical outcomes of patients with chronic pain who are receiving daily opioid therapy.

This study has limitations. First, as previously noted,^[@bibr18-1744806919848929][@bibr19-1744806919848929]--[@bibr20-1744806919848929]^ patients receiving care at our pain rehabilitation center may not be fully representative of a random community sample of adults with chronic pain. However, in a population-based study of chronic pain (N = 3575) conducted in the catchment area of our tertiary referral medical center, 96% of individuals were white and 56% were female.^[@bibr57-1744806919848929]^ Despite these demographic similarities, referral bias could have influenced the study findings. Second, the effects of a single COMT SNP on pain perception were investigated which does not represent the full breadth of COMT activity. Thus, the study findings may have been influenced by other COMT polymorphisms. Third, as previously noted,^[@bibr18-1744806919848929]^ a validated substance abuse assessment was not performed. This is important because the COMT Val158Met polymorphism has been associated with heroin addiction, alcohol abuse, cocaine dependence, and methamphetamine abuse.^[@bibr58-1744806919848929],[@bibr59-1744806919848929]^ This is important because individuals with substance abuse disorders have been long recognized to harbor alterations in pain perception.^[@bibr60-1744806919848929]^ Thus, inclusion of substance abuse as an independent variable in the multivariate models could have influenced the associations between HP perception and the COMT Val158Met polymorphism. Finally, the CASE IV system is designed to assess vibration detection thresholds and cooling detection thresholds (CDTs), but the HP modality was solely used in this study. Based on our previous work, we have not observed any associations between CDT and clinical factors associated with chronic pain.^[@bibr27-1744806919848929]^ It is important to note that the CASE IV QST modality of CDT is not a measure of cold pain threshold or maximal cold pain tolerance; rather, CDT is a measure of the threshold for perceiving a sensation of cooling.^[@bibr27-1744806919848929]^ However, the potential associations between COMT Val158Met polymorphisms and other QST modalities, including conditioned pain modulation and temporal summation, should be investigated in future studies.

In summary, among patients with chronic pain who were receiving daily opioids, the Val/Met genotype of the COMT Val158Met polymorphism was associated with hyperalgesia compared to the Val/Val and Met/Met genotypes using a measure of HP perception that has been previously indicative of OIH in other heterogeneous samples of adults with chronic pain. This study contributes to the emerging understanding of how COMT activity influences the pain perception in the context of daily opioid use, and these findings may be useful in the design of future trials aimed at investigating the potential efficacy of ß~2~-AR antagonism for OIH.
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